Kidney Cancer

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.

Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.

Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

A physician’s social network is important to determining the adoption of high-value cancer drugs, as researchers have determined peer influence had a strong association with the adoption of Avastin among oncologists across the nation.

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.

Here is a list of clinical trials that are currently happening within the kidney cancer space.

In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.

When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.

The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

Drug duos that hit kidney cancer with immunotherapy and targeted treatment offer a better alternative to single agents.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

The tumors of patients with non-small cell lung and renal cell cancer shrunk following treatment with pegilodecakin plus immunotherapy.

From a Hallmark Channel actor revealing a kidney cancer diagnosis to a donor match first-time meeting 20 years later, here’s what is making headlines in the cancer space this week.

Patients with renal cell carcinoma who were treated with a targeted therapy lived three months longer than people who received older treatments.

One expert discusses the “extremely interesting and extremely dynamic” field of renal cell carcinoma, and how recent research and FDA actions could offer hope for patients and their doctors.

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.